论文部分内容阅读
目的探讨胃癌组织中HER-2基因的扩增与胃癌患者临床病理特征及预后之间的关系。方法采用荧光原位杂交技术(FISH)检测119例胃癌组织中的HER-2基因扩增状态,分析HER-2基因与胃癌临床病理参数及预后的相关性。结果 119例胃癌组织中,HER-2阳性19例(16%),阴性100例(84%)。HER-2基因扩增与肿瘤部位、lauren分型、脉管浸润、淋巴结转移有关(P<0.05),与患者性别、年龄、肿瘤大小、肿瘤分化程度、肿瘤浸润深度无关(P>0.05)。HER-2阳性和阴性患者的总体生存率差异不显著(P>0.05)。结论胃癌HER-2基因与患者的部分临床病理特征有关,可作为判断胃癌生物学行为的重要指标,但HER-2基因的扩增不能作为胃癌的独立预后指标,其与预后的关系还需进一步研究。
Objective To investigate the relationship between the amplification of HER-2 gene in gastric cancer and the clinicopathological characteristics and prognosis of gastric cancer. Methods The amplification status of HER-2 gene in 119 cases of gastric cancer was detected by fluorescence in situ hybridization (FISH), and the correlation between HER-2 gene and the clinicopathological parameters and prognosis of gastric cancer was analyzed. Results In 119 cases of gastric cancer, HER-2 was positive in 19 cases (16%) and negative in 100 cases (84%). The amplification of HER-2 gene was correlated with tumor location, lauren classification, vascular invasion and lymph node metastasis (P <0.05), but not with gender, age, tumor size, tumor differentiation and tumor invasion depth (P> 0.05). There was no significant difference in overall survival between HER-2 positive and negative patients (P> 0.05). Conclusion The HER-2 gene in gastric cancer is related to some clinical and pathological features of gastric cancer, which may be used as an important index to judge the biological behavior of gastric cancer. However, HER-2 gene amplification can not be used as an independent prognostic indicator of gastric cancer. the study.